CLINICAL TRIAL
Treatment for GastroEsophageal Cancer
Metastatic
Waitlist Available · 18+ · All Sexes · Houston, TX
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
See full descriptionAbout the trial for GastroEsophageal Cancer
Eligible Conditions
GastroEsophageal Cancer · Gastrostomy · Gastric
Treatment Groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.
Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:View All
You are able to speak and read English or Spanish (for patients enrolled at MD Anderson and Mayo Clinic), English or Korean (for patients enrolled at Yonsei), and English or Japanese (for patients enrolled at Keio). show original
Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention
Age ≥ 18
Odds of EligibilitySimilar Trials
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Approximate Timelines
Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 3 months after surgery
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months after surgery
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like
Measurement Requirements
This trial is evaluating whether Treatment will improve 1 primary outcome in patients with GastroEsophageal Cancer. Measurement will happen over the course of 3 months after surgery.
(MDASI-GI) MD Anderson Symptom Inventory Questionnaire
3 MONTHS AFTER SURGERY3 MONTHS AFTER SURGERY
Appetite level (reported on a 0-10 scale, in Q8 of MDASI-GI) scale 0-not present-10 as bad as you can imagePatient Q & A Section
Ask a question about the study
Other questions from users
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any geographic restrictions to consider when applying for this trial?
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
Will my insurance cover participating in this trial?
In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.
See if you qualify for this trial
Get access to this novel treatment for GastroEsophageal Cancer by sharing your contact details with the study coordinator.